Short answer
Tvardi Therapeutics, Inc. (TVRD) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$6M
- −10.8% YoY · +5.2% QoQ
- EPS (diluted)
- −$0.44
- +4.3% YoY · +35.3% QoQ
Source: XBRL data from the Tvardi Therapeutics, Inc. (TVRD) Q3 2026 10-Q on SEC EDGAR. USD.
Tvardi Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved or commercialized
- Net loss $6.1M vs $5.5M YoY, operating expenses $6.3M vs $5.9M
- Best program TTI-101 HCC spending $2.4M, up 307.0% YoY; TTI-109 spending $1.0M, down 49.0%
- Cash $22.3M at September 30, 2026; operating cash use $21.5M for nine months
- ATM proceeds $13.3M; substantial doubt about funding operations for at least one year, additional capital required
Risk Factors
- No material changes identified from the March 31, 2026 Form 10-K
- Clinical-stage business risk: adverse events could impair financial condition, results, and growth prospects
- Market risk: adverse developments could reduce the common stock price
- Disclosure risk: unknown or currently immaterial risks could impair operations and stock value
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tvardi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.